Summary
33.26 0.40(1.22%)09/27/2024
Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Inc. (CLDX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.37 | -19.32 | -13.00 | -11.85 | -20.30 | 21.65 | 1,432.72 | -96.21 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 33.26 | |
| Open | 32.20 | |
| High | 33.32 | |
| Low | 31.22 | |
| Volume | 1,223,384 | |
| Change | 0.45 | |
| Change % | 1.37 | |
| Avg Volume (20 Days) | 1,522,951 | |
| Volume/Avg Volume (20 Days) Ratio | 0.80 | |
| 52 Week Range | 22.11 - 53.18 | |
| Price vs 52 Week High | -37.46% | |
| Price vs 52 Week Low | 50.43% | |
| Range | 3.29 | |
| Gap Up/Down | -4.55 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,178 | |
| EBIDTA | -147,122,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 70.29 | |
| Book Value | 12.7240 | |
| Earnings Per Share | -2.8600 | |
| EPS Estimate Current Quarter | -0.6900 | |
| EPS Estimate Next Quarter | -0.7100 | |
| EPS Estimate Current Year | -2.3100 | |
| EPS Estimate Next Year | -2.7800 | |
| Diluted EPS (TTM) | -2.8600 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -260.3077 | |
| Return on asset (TTM) | -0.1573 | |
| Return on equity (TTM) | -0.2539 | |
| Revenue TTM | 6,072,000 | |
| Revenue per share TTM | 0.1180 | |
| Quarterly Revenue Growth (YOY) | -0.8390 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -79,901,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.0085 | |
| Revenue Enterprise Value | 313.4705 | |
| EBITDA Enterprise Value | -15.5186 | |
| Shares | ||
| Shares Outstanding | 65,910,500 | |
| Shares Float | 62,265,036 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.12 | |
| Insider (%) | 0.34 | |
| Institutions (%) | 99.39 | |
09/26 11:30 EST - zacks.com
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
09/25 10:45 EST - globenewswire.com
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease - - Well tolerated through 52 weeks - - Enrollment to Global Phase 3 CSU trials underway - - Company to host webcast today at 12:00 pm ET/6:00 pm CEST -
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease - - Well tolerated through 52 weeks - - Enrollment to Global Phase 3 CSU trials underway - - Company to host webcast today at 12:00 pm ET/6:00 pm CEST -
09/16 08:01 EST - globenewswire.com
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 being held in Amsterdam on September 25-28, 2024.
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 being held in Amsterdam on September 25-28, 2024.
09/12 16:01 EST - globenewswire.com
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
08/08 18:25 EST - zacks.com
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.
08/08 16:01 EST - globenewswire.com
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
07/29 16:01 EST - globenewswire.com
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.
07/16 08:01 EST - globenewswire.com
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients -
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients -
06/04 16:01 EST - globenewswire.com
Celldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
Celldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
06/02 09:01 EST - globenewswire.com
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU -
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU -
05/27 11:00 EST - zacks.com
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
05/20 04:43 EST - https://www.defenseworld.net
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Swiss National Bank
Swiss National Bank boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,000 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the period. Swiss National Bank owned about 0.21% of Celldex Therapeutics worth $3,847,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also added to or reduced their stakes in CLDX. Teacher Retirement System of Texas increased its stake in shares of Celldex Therapeutics by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 522 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 805 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 821 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Celldex Therapeutics by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock valued at $852,000 after acquiring an additional 954 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Celldex Therapeutics by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock worth $1,041,000 after acquiring an additional 962 shares during the last quarter. Celldex Therapeutics Trading Down 4.3 % Shares of CLDX opened at $38.21 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18. The firm has a market capitalization of $2.52 billion, a P/E ratio of -13.41 and a beta of 1.60. The firm has a 50-day moving average price of $40.41 and a 200 day moving average price of $37.93. Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year. Analyst Ratings Changes A number of research analysts have weighed in on CLDX shares. Guggenheim raised their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.00. View Our Latest Stock Analysis on CLDX Celldex Therapeutics Profile (Free Report) Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. See Also Five stocks we like better than Celldex Therapeutics How to Invest in the FAANG Stocks MarketBeat Week in Review – 5/13 – 5/17 Dividend Screener: How to Evaluate Dividend Stocks Before Buying Take-Two Interactive Software Offers 2nd Chance for Investors Golden Cross Stocks: Pattern, Examples and Charts Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Swiss National Bank
Swiss National Bank boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,000 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the period. Swiss National Bank owned about 0.21% of Celldex Therapeutics worth $3,847,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also added to or reduced their stakes in CLDX. Teacher Retirement System of Texas increased its stake in shares of Celldex Therapeutics by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 522 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 805 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 821 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Celldex Therapeutics by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock valued at $852,000 after acquiring an additional 954 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Celldex Therapeutics by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock worth $1,041,000 after acquiring an additional 962 shares during the last quarter. Celldex Therapeutics Trading Down 4.3 % Shares of CLDX opened at $38.21 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18. The firm has a market capitalization of $2.52 billion, a P/E ratio of -13.41 and a beta of 1.60. The firm has a 50-day moving average price of $40.41 and a 200 day moving average price of $37.93. Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year. Analyst Ratings Changes A number of research analysts have weighed in on CLDX shares. Guggenheim raised their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.00. View Our Latest Stock Analysis on CLDX Celldex Therapeutics Profile (Free Report) Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. See Also Five stocks we like better than Celldex Therapeutics How to Invest in the FAANG Stocks MarketBeat Week in Review – 5/13 – 5/17 Dividend Screener: How to Evaluate Dividend Stocks Before Buying Take-Two Interactive Software Offers 2nd Chance for Investors Golden Cross Stocks: Pattern, Examples and Charts Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/15 08:01 EST - globenewswire.com
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN where mast cells are associated with pruritic sensory neurons in PN lesions.
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN where mast cells are associated with pruritic sensory neurons in PN lesions.
05/09 10:56 EST - zacks.com
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
05/06 16:01 EST - globenewswire.com
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study - - Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 -
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 - - Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study - - Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 -
04/17 08:01 EST - globenewswire.com
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temperatures below skin temperature in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria—chronic spontaneous urticaria (CSU).
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temperatures below skin temperature in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria—chronic spontaneous urticaria (CSU).
04/09 10:36 EST - zacks.com
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
04/08 13:01 EST - zacks.com
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
04/08 10:35 EST - zacks.com
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
03/20 10:56 EST - zacks.com
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.